Aqilion project company Trophea to be liquidated

Today AQILION AB announced that the extraordinary general meeting of the project company Trophea AB, with its wholly owned subsidiary Trophea Development AB, resolved to liquidate the companies. According to the decision, liquidation will begin on December 28, 2019.

Aqilion presents Nomination Committee for the 2020 Annual General Meeting

The Nomination Committee has been appointed and comprises the following members:
Helena Arcombe, appointed by the shareholder Länsförsäkringar
Malin Ruijsenaars, appointed by the shareholders Grenspecialisten AB and LMK Forward AB
Clas Runnberg, appointed to represent other shareholders
Lena Mårtensson, appointed to represent Aqilion’s network of advisors

Aqilion sells shareholdings in portfolio company Glactone Pharma

AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB. The purchase price is divided into a smaller amount as initial payment at the time of takeover and an additional payment based on Glactone Pharma’s future performance.


Aqilion is a Swedish life science company

We believe the best source of new treatments comes from identifying, shaping and strengthening early drug innovation. We seek ideas that could potentially both improve patient quality of life and streamline health care. 

We want to challenge and apply science in combination with creativity and entrepreneurship to maximize health care value for society. 

The word “Aqilion” derives from Aquila, the Latin for eagle, and from the Aquila constellation, seen in the Nordic sky. The name symbolizes the concept of a constellation of partners, as well as the ability to exercise an “eagle eye” by applying the company’s extensive experience to identify and pursue unique opportunities.

For more info contact us here!

© Copyright 2019 Aqilion AB